U.S. Household Products Stock News

NYSE:TROX
NYSE:TROXChemicals

Tronox Holdings (TROX) Is Up 7.1% After Wider 2025 Losses And Fresh Shelf Registration Filed - Has The Bull Case Changed?

In February 2026, Tronox Holdings plc reported fourth-quarter 2025 sales of US$730 million and a net loss of US$176 million, with full-year 2025 sales of US$2.90 billion and a net loss of US$470 million, before subsequently filing an omnibus shelf registration for ordinary shares, preference shares, and debt securities. The combination of widening losses and a new universal shelf registration highlights Tronox’s need for financial flexibility at a time of rising earnings pressure and...
NYSE:KOS
NYSE:KOSOil and Gas

Kosmos Energy Reshapes Portfolio As Ghana Extensions Target Stronger Cash Flows

Kosmos Energy (NYSE:KOS) has secured extensions for major Ghana oil and gas licenses to 2040. The company is reshaping its portfolio, including acquiring a key FPSO, exiting Equatorial Guinea assets, and focusing on the Gulf of Mexico via a new alliance with Shell. Management is targeting a 20% reduction in operating costs and a 10% reduction in net debt in 2026, supported by new bond financing. Kosmos Energy, trading at $2.4, has seen sharp share price swings, with the stock up 16.5% over...
NYSE:FIGS
NYSE:FIGSLuxury

Why FIGS (FIGS) Is Up 56.9% After Strong Q4 Beat And 2026 Growth Outlook

In late February 2026, FIGS, Inc. reported fourth-quarter 2025 revenue of US$201.9 million and net income of US$18.51 million, capping a full-year performance of US$631.1 million in sales and US$34.25 million in net income with sharply higher earnings per share versus 2024. Management paired these results with an outlook for 10% to 12% revenue growth in 2026, underscoring momentum from a larger active customer base, international expansion and improved operating margins. We’ll now examine...
NasdaqGS:AARD
NasdaqGS:AARDPharmaceuticals

Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101

Aardvark Therapeutics recently voluntarily paused its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, and no longer expects to report topline data in the third quarter of 2026, with updated guidance now planned for the second quarter of 2026. The pause affects Aardvark’s lead asset in a rare disease setting where ARD-101 already holds both Orphan Drug and Rare Pediatric Disease designations from the FDA. We will now examine how the pause of the HERO Phase 3 trial for...
NYSE:HE
NYSE:HEElectric Utilities

What Hawaiian Electric Industries (HE)'s Wildfire-Era Profit Recovery Means For Shareholders

Hawaiian Electric Industries reported full-year 2025 revenue of US$3.09 billion, down slightly from US$3.22 billion in 2024, while swinging from a very large net loss to net income of US$123.12 million, or US$0.71 in basic and diluted earnings per share from continuing operations. The earnings rebound coincided with progress on Maui wildfire-related settlements, funded by insurance, and regulatory approval of a multi-year wildfire safety plan that supports both risk reduction and grid...
NYSE:NPO
NYSE:NPOMachinery

Is It Too Late To Consider Enpro (NPO) After Its Strong Multi Year Share Price Run?

If you are wondering whether Enpro's current share price really reflects its underlying worth, this article walks through what the numbers actually say about value. Enpro's share price recently closed at US$264.05, with returns of 10.6% over 30 days, 20.5% year to date, 49.2% over 1 year, 155.4% over 3 years and 205.4% over 5 years. These figures may catch the eye of investors thinking about future risk and reward. Recent coverage around Enpro has focused on its role within the capital goods...
NasdaqCM:UFPT
NasdaqCM:UFPTMedical Equipment

UFP Technologies Deepens Intuitive Surgical Ties With Expanded Long Term Deal

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...
NYSE:TFC
NYSE:TFCBanks

Is Truist Financial (TFC) Pricing Reflect Its Recent Returns And Valuation Metrics

If you are wondering whether Truist Financial's current share price really lines up with its underlying worth, this article will walk through the key numbers that matter most. Over the short term, the stock has seen a 1.1% decline over 7 days and a 3.6% decline over 30 days. The longer term picture shows a 14.3% return over 1 year, 26.4% over 3 years, and 5.1% over 5 years from a last close of US$49.55. Recent market attention around large US banks has kept Truist Financial in focus,...
NasdaqGS:PENN
NasdaqGS:PENNHospitality

Is PENN Entertainment (PENN) Now Attractively Priced After Recent Share Price Rebound?

This article examines whether PENN Entertainment at around US$14.85 appears attractively priced or potentially a value trap, by reviewing what the available numbers indicate about the stock. The share price has moved sharply in the short term, with a 22% return over the last 7 days and 15.7% over the last 30 days. This contrasts with a 28.5% decline over 1 year and a 51% decline over 3 years. Recent headlines have focused on PENN Entertainment's position in the US gaming and entertainment...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

Is SPS Commerce (SPSC) Now Attractive After A 55% One Year Share Price Slump

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...
NasdaqGM:VCYT
NasdaqGM:VCYTBiotechs

Veracyte (VCYT) Valuation Check After Mixed Short And Long Term Share Price Performance

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...
NYSE:FLR
NYSE:FLRConstruction

Is Fluor (FLR) Pricing Reflect Recent 38% Rally And Mixed Valuation Signals

If you are looking at Fluor and wondering whether the current share price gives you good value, you are not alone. This article focuses squarely on what you might be paying for compared to what you are getting. After closing at US$50.91, the stock has seen a 1.4% decline over the last 7 days, a 10.2% gain over 30 days, a 22.1% return year to date, and a 37.9% return over the past year, which may change how investors think about both upside and risk. Recent attention on Fluor has been driven...
NYSE:XZO
NYSE:XZOInsurance

Exzeo Group Flood Partnership Tests Valuation Concerns And Growth Hopes

Exzeo Group has entered into a new partnership with Tokio Marine Highland to distribute TMH2O residential flood insurance. The collaboration expands Exzeo’s property insurance offerings and supports its ambitions as a multi-line, technology driven platform. For investors tracking NYSE:XZO, this announcement comes as the stock trades at $16.1, with a 3.7% gain over the past week and a 20.8% decline over the past month. Year to date, shares show a 29.3% decline, so this move may stand out as...
NasdaqGS:ARHS
NasdaqGS:ARHSSpecialty Retail

Arhaus (ARHS) Valuation Check After Recent Share Price Pullback

Why Arhaus Stock Is Drawing Attention Now Arhaus (ARHS) has pulled back recently, with the share price down over the past month and past 3 months. This move is prompting investors to reassess how its current valuation lines up with the underlying business. The company reports annual revenue of US$1,379.2m and net income of US$67.3m, and some models suggest the shares trade at a sizeable discount to certain intrinsic value estimates. This can attract interest from value oriented investors. See...
NasdaqCM:USAU
NasdaqCM:USAUMetals and Mining

Is U.S. Gold (USAU) Using Its Conference Spotlight To Recast Management Credibility With Investors?

U.S. Gold Corp. recently presented at the Emerging Growth Virtual Conference on February 25, 2026, with Executive Chairman Luke Anthony Norman addressing investors. This appearance gave the company a platform to highlight its latest corporate developments and project plans directly to a broad investment audience. We’ll now explore how U.S. Gold Corp.’s Emerging Growth Virtual Conference presentation could shape its investment narrative and investor expectations. The best AI stocks today may...
NYSE:DTM
NYSE:DTMOil and Gas

What DT Midstream (DTM)'s Strong 2025 Results and Bigger Project Pipeline Mean For Shareholders

DT Midstream, Inc. reported full-year 2025 results showing sales rising to US$1,243 million and net income to US$441 million, alongside a 7% dividend increase to US$0.88 per share and a US$396.99 million shelf registration for 3,000,000 shares related to its ESOP. Management’s disclosure that its project pipeline is several times larger than the announced US$3.40 billion capital plan, with growth expected to outpace a 7% annualized rate through the rest of the decade, points to a materially...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Viridian Therapeutics (VRDN) Valuation After Wider Q4 Loss And Ongoing Thyroid Eye Disease Regulatory Reviews

Viridian Therapeutics (VRDN) is in focus after reporting a larger than expected Q4 2025 loss and lower than forecast revenue. Its lead thyroid eye disease candidate remains under FDA Priority Review and EMA review. See our latest analysis for Viridian Therapeutics. At a share price of US$30.25, Viridian’s 1 day share price return of 2.96% and 7 day share price return of 7.77% follow a weaker 30 day share price return of an 8.33% decline. The 1 year total shareholder return of 109.92%...
NYSE:TRV
NYSE:TRVInsurance

The Bull Case For Travelers (TRV) Could Change Following AI-Powered Claims Assistant Rollout – Learn Why

In February 2026, Travelers Companies launched its AI Claim Assistant, an agentic voice solution built on OpenAI models and APIs to handle auto damage claim calls, streamline submissions, and free claim professionals to focus on more complex issues while retraining call center staff into higher-value roles. The rollout highlights how Travelers is embedding advanced analytics and AI directly into its claims workflow, blending automation with live human support to potentially raise service...
NasdaqGS:OLPX
NasdaqGS:OLPXPersonal Products

A Look At Olaplex Holdings (OLPX) Valuation After The No.3PLUS Complete Repair Treatment Launch

What the No.3PLUS launch could mean for Olaplex Holdings (OLPX) Olaplex Holdings (OLPX) has launched No.3PLUS Complete Repair Treatment, a pre-shampoo product built on its Bond Building Technology and new Damage Defense Cationic Complex, supported by a broad retail rollout and a science themed marketing campaign. See our latest analysis for Olaplex Holdings. Despite today’s 5.6% one day share price decline, Olaplex’s 90 day share price return of 36.9% and 12.6% year to date gain suggest...
NYSE:BBU
NYSE:BBUIndustrials

Should Bullish Analyst Coverage on BBU’s Valuation Reframe How Investors Read Brookfield Business Partners’ Dealmaking Ambitions?

In recent days, CIBC initiated coverage on Brookfield Business Partners L.P. with an Outperformer rating, joining other brokers that have expressed confidence in the business. Analysts have highlighted Brookfield Business Partners’ connection to the broader Brookfield group, its cornerstone Clarios holding, and an apparent discount to net asset value as central to their positive view. We will now look at how this wave of bullish analyst coverage, especially around valuation and dealmaking...
NYSE:ASB
NYSE:ASBBanks

Associated Banc-Corp Taps New Data Chief To Shape Growth And Risk

Associated Banc-Corp (NYSE:ASB) has appointed Alexander Bush as Executive Vice President and Chief Data Officer. Bush will lead the company’s enterprise data strategy and governance across the organization. For investors watching NYSE:ASB, this move comes as the stock trades at $26.58, with a 1 year return of 13.8% and a 5 year return of 44.2%. Those figures indicate that the company has been taking steps to refine its business, and a dedicated data leader represents another layer in that...
NYSE:DCI
NYSE:DCIMachinery

Donaldson Company (DCI) Is Down 10.3% After Earnings Miss, Tighter Guidance And Major Acquisition

In late February 2026, Donaldson Company, Inc. reported fiscal second-quarter results showing sales of US$896.3 million with slightly lower net income of US$92.5 million, while also tightening its full-year earnings guidance amid margin pressures. At the same time, Donaldson announced its largest-ever acquisition and introduced its new ArmorSeal air filtration technology, signaling a continued push into higher-value filtration applications even as near-term profit expectations were reduced...
NYSE:XPO
NYSE:XPOTransportation

Do XPO’s (XPO) Lighter, More Frequent Shipments Hint At A Higher-Quality Freight Mix?

XPO recently reported preliminary February 2026 less-than-truckload operating metrics, showing a 0.2% year-over-year increase in tonnage per day, driven by a 3.0% rise in shipments per day and a 2.8% decline in average shipment weight versus February 2025. This mix of more frequent but lighter shipments offers a fresh read on freight demand quality in XPO’s core less-than-truckload business. We’ll now examine how the rise in shipments per day and lighter weights shapes XPO’s existing...
NasdaqCM:VRRM
NasdaqCM:VRRMProfessional Services

Why Verra Mobility (VRRM) Is Down 10.1% After Strong 2025 Results And Major Hawaii Contract

Verra Mobility recently reported past fourth-quarter and full-year 2025 results showing higher revenue of US$257.86 million and US$979.08 million respectively, alongside a swing to net income of US$18.88 million for the quarter and US$136.63 million for the year. The company also secured a 10-year, approximately US$160 million statewide automated traffic enforcement contract with the Hawaii Department of Transportation, signaling a long-duration stream of enforcement-related service...